Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.19), $0.36 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $81.73 million versus the consensus estimate of $78.05 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.